MY145722A - Diazabicyclic central nervous system active agents - Google Patents

Diazabicyclic central nervous system active agents

Info

Publication number
MY145722A
MY145722A MYPI20055633A MYPI20055633A MY145722A MY 145722 A MY145722 A MY 145722A MY PI20055633 A MYPI20055633 A MY PI20055633A MY PI20055633 A MYPI20055633 A MY PI20055633A MY 145722 A MY145722 A MY 145722A
Authority
MY
Malaysia
Prior art keywords
nervous system
active agents
central nervous
system active
diazabicyclic
Prior art date
Application number
MYPI20055633A
Other languages
English (en)
Inventor
Michael R Schrimpf
Karin R Tietje
Richard B Toupence
Jianguo Ji
Anwer Basha
William H Bunnelle
Jerome F Daanen
Jennifer Mary Pace
Kevin B Sippy
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/833,914 external-priority patent/US6809105B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MY145722A publication Critical patent/MY145722A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI20055633A 2000-04-27 2001-04-26 Diazabicyclic central nervous system active agents MY145722A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55994300A 2000-04-27 2000-04-27
US09/833,914 US6809105B2 (en) 2000-04-27 2001-04-12 Diazabicyclic central nervous system active agents

Publications (1)

Publication Number Publication Date
MY145722A true MY145722A (en) 2012-03-30

Family

ID=27072208

Family Applications (3)

Application Number Title Priority Date Filing Date
MYPI20055633A MY145722A (en) 2000-04-27 2001-04-26 Diazabicyclic central nervous system active agents
MYPI20011984A MY137020A (en) 2000-04-27 2001-04-26 Diazabicyclic central nervous system active agents
MYPI20094589A MY168244A (en) 2000-04-27 2005-03-07 Polyester polymer particles having a small surface to center molecular weight gradient

Family Applications After (2)

Application Number Title Priority Date Filing Date
MYPI20011984A MY137020A (en) 2000-04-27 2001-04-26 Diazabicyclic central nervous system active agents
MYPI20094589A MY168244A (en) 2000-04-27 2005-03-07 Polyester polymer particles having a small surface to center molecular weight gradient

Country Status (22)

Country Link
EP (3) EP1284976A2 (https=)
JP (2) JP4981232B2 (https=)
KR (4) KR100947187B1 (https=)
CN (3) CN100430398C (https=)
AR (1) AR030421A1 (https=)
AU (2) AU2001266559C1 (https=)
BG (2) BG66151B1 (https=)
BR (1) BR0107246A (https=)
CA (2) CA2407094C (https=)
CZ (4) CZ302072B6 (https=)
HK (1) HK1054375A1 (https=)
HU (1) HUP0300602A3 (https=)
IL (3) IL152231A0 (https=)
MX (1) MXPA02010594A (https=)
MY (3) MY145722A (https=)
NO (1) NO324250B1 (https=)
NZ (1) NZ521734A (https=)
PE (1) PE20011305A1 (https=)
PL (2) PL358340A1 (https=)
SK (2) SK287658B6 (https=)
TW (4) TWI357903B (https=)
WO (1) WO2001081347A2 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
SE0100326D0 (sv) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
AU2003278529A1 (en) * 2002-11-21 2004-06-15 Pfizer Products Inc. 3-amino-piperidine derivatives and processes for their preparation
US20040242641A1 (en) 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US7354937B2 (en) 2004-05-21 2008-04-08 Abbott Laboratories (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
US20050261348A1 (en) * 2004-05-21 2005-11-24 Buckley Michael J (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
CA2565211A1 (en) 2004-04-29 2005-11-24 Abbott Laboratories Amino-tetrazoles analogues and methods of use
US7351833B2 (en) 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7425556B2 (en) * 2005-12-20 2008-09-16 Astrazeneca Ab Compounds and uses thereof
US20070184490A1 (en) * 2006-01-17 2007-08-09 Marleen Verlinden Neuronal nicotinic receptor ligands and their use
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
EP2129672B1 (en) 2007-03-23 2011-05-18 Abbott Laboratories Azaadamantane ester and carbamate derivatives and methods of use thereof
CN101809021B (zh) 2007-09-11 2013-04-24 雅培制药有限公司 八氢-吡咯并[3,4-b]吡咯n-氧化物
AR069126A1 (es) 2007-10-31 2009-12-30 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
WO2009067586A1 (en) * 2007-11-21 2009-05-28 Abbott Laboratories Biaryl substituted diazabicycloalkane derivatives
CA2707671C (en) 2007-12-07 2016-02-02 Abbott Gmbh & Co. Kg 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
CA2707669C (en) 2007-12-07 2016-07-05 Wilfried Braje 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
US8703775B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
PL2245028T3 (pl) 2007-12-18 2012-07-31 Actelion Pharmaceuticals Ltd Pochodne 5-aminocyklilometyloksazolidyn-2-onu
MY157597A (en) 2008-04-11 2016-06-30 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase
US8148408B2 (en) 2008-05-09 2012-04-03 Abbott Laboratories Selective substituted pyridine ligands for neuronal nicotinic receptors
US8263632B2 (en) * 2009-03-24 2012-09-11 Vertex Pharmaceuticals Incoporated Aminopyridine derivatives having Aurora A selective inhibitory action
US8399465B2 (en) 2009-05-14 2013-03-19 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
WO2010151815A2 (en) 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
NZ598985A (en) 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
WO2011050202A1 (en) * 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
JP5847087B2 (ja) * 2009-10-23 2016-01-20 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
KR101655787B1 (ko) 2014-05-08 2016-09-22 대우조선해양 주식회사 선박의 하이브리드 공기조화시스템 및 그 방법, 그리고 이를 포함하는 선박 또는 해양구조물
KR20160021679A (ko) 2014-08-18 2016-02-26 대우조선해양 주식회사 극저온 환경의 장비용 히팅장치 및 방법 그리고 이를 구비하는 선박
RU2017118562A (ru) 2014-10-31 2018-11-30 Индивиор ЮКей Лимитед Соединения-антагонисты дофаминового d3-рецептора
MD3426251T2 (ro) 2016-03-10 2022-09-30 Janssen Pharmaceutica Nv Metode de tratament al depresiei utilizând antagoniști ai receptorului orexină-2
JP7214632B2 (ja) 2016-07-21 2023-01-30 バイオジェン エムエー インク． ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
US11266640B2 (en) * 2017-09-20 2022-03-08 Hangzhou Innogate Pharma Co., Ltd. Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitor
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
WO2020100011A1 (en) 2018-11-14 2020-05-22 Janssen Pharmaceutica Nv Improved synthetic methods of making fused heterocyclic compounds as orexin receptor modulators
CN112010859B (zh) * 2019-05-30 2022-07-19 中国科学院上海药物研究所 一种并环化合物、其制备方法和用途
PH12022550295A1 (en) 2019-08-07 2022-11-21 Janssen Pharmaceutica Nv Improved synthetic methods of making (2h-1,2,3-triazol-2-yl)phenyl compounds as orexin receptor modulators
CN112047878B (zh) * 2020-10-15 2022-04-19 郑州猫眼农业科技有限公司 4-溴-6-氯吡啶-2-羧酸的制备方法
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2079391T3 (es) * 1989-04-17 1996-01-16 Bayer Ag Procedimiento para la obtencion de 2,7-diazabiciclo(3.3.0)octanos.
NL9201810A (nl) 1992-10-19 1994-05-16 Dsm Nv Werkwijze voor de omzetting van een olefine of een olefinemengsel.
CA2112165C (en) 1992-12-25 2003-04-08 Makoto Takemura Bicyclic amine derivatives
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
US5472958A (en) 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
EP0842178B1 (en) * 1995-07-28 2001-03-28 Abbott Laboratories Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission
GB9519558D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
JPH09172344A (ja) 1995-12-19 1997-06-30 Murata Mfg Co Ltd 圧電共振子
US5733912A (en) 1997-02-19 1998-03-31 Abbott Laboratories 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
KR100589872B1 (ko) * 1997-05-30 2006-06-15 뉴로서치 에이/에스 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법
WO1998054182A1 (en) * 1997-05-30 1998-12-03 Neurosearch A/S 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS
GB9722343D0 (en) * 1997-10-22 1997-12-17 British Telecomm Distributed virtual environment
EE04588B1 (et) * 1997-10-27 2006-02-15 Neurosearch A/S Heteroarüüldiasatsükloalkaanid kui atsetüülkoliini nikotiinretseptorite kolinergilised ligandid, nende kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
WO1999051602A1 (en) * 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company Azatricyclo[3.3.1.1] decane derivatives and pharmaceutical compositions containing them
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP2000026408A (ja) 1998-07-02 2000-01-25 Dai Ichi Seiyaku Co Ltd 対掌体的に純粋なピロリジン誘導体、その塩、それらの製造方法
US6804251B1 (en) 1998-11-12 2004-10-12 Broadcom Corporation System and method for multiplexing data from multiple sources
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
ES2305373T3 (es) * 1999-01-29 2008-11-01 Abbott Laboratories Derivados diazabiciclicos como ligandos del receptor nicotinico de la acetilcolina.
NZ513575A (en) * 1999-05-04 2003-07-25 Neurosearch As Heteroaryl diazabicycloalkanes useful for treating or preventing a disease or a disorder responsive to the activity of nAChR modulators
WO2000071534A1 (en) * 1999-05-21 2000-11-30 Abbott Laboratories Heterocyclic substituted aminoazacycles useful as central nervous system agents
US6815438B2 (en) * 1999-12-14 2004-11-09 Neurosearch A/S Heteroaryl-diazabicycloalkanes

Also Published As

Publication number Publication date
WO2001081347A3 (en) 2002-01-31
BG66151B1 (bg) 2011-08-31
PE20011305A1 (es) 2001-12-31
BR0107246A (pt) 2002-10-01
MY168244A (en) 2018-10-15
TW200909432A (en) 2009-03-01
CZ302795B6 (cs) 2011-11-16
NO20025107L (no) 2002-12-19
KR20090013833A (ko) 2009-02-05
NO324250B1 (no) 2007-09-17
CN100430398C (zh) 2008-11-05
CZ20023765A3 (cs) 2003-02-12
CA2407094C (en) 2009-11-17
TW201141871A (en) 2011-12-01
HK1054375A1 (zh) 2003-11-28
CN101935322A (zh) 2011-01-05
PL358340A1 (en) 2004-08-09
CA2683045A1 (en) 2001-11-01
HUP0300602A3 (en) 2005-12-28
TWI311137B (en) 2009-06-21
TWI357903B (en) 2012-02-11
BG110620A (bg) 2010-07-30
EP2298775A1 (en) 2011-03-23
CA2407094A1 (en) 2001-11-01
SK287273B6 (sk) 2010-05-07
TW200617013A (en) 2006-06-01
WO2001081347A2 (en) 2001-11-01
KR20090121385A (ko) 2009-11-25
CZ302072B6 (cs) 2010-09-29
IL152231A0 (en) 2003-05-29
AU2001266559C1 (en) 2005-11-17
JP4981232B2 (ja) 2012-07-18
AU2001266559B2 (en) 2005-03-03
CN102863441A (zh) 2013-01-09
IL203035A (en) 2010-12-30
KR100961406B1 (ko) 2010-06-09
NZ521734A (en) 2004-10-29
SK287658B6 (sk) 2011-05-06
IL177316A (en) 2010-06-30
BG107303A (bg) 2003-07-31
EP2295437A1 (en) 2011-03-16
JP2003531210A (ja) 2003-10-21
KR100947187B1 (ko) 2010-03-12
KR100947188B1 (ko) 2010-03-12
PL398491A1 (pl) 2012-06-04
AR030421A1 (es) 2003-08-20
CZ302038B6 (cs) 2010-09-15
JP2012041349A (ja) 2012-03-01
IL177316A0 (en) 2006-12-10
SK16812002A3 (sk) 2003-04-01
HUP0300602A2 (hu) 2003-06-28
KR100899950B1 (ko) 2009-05-28
MY137020A (en) 2008-12-31
AU6655901A (en) 2001-11-07
NO20025107D0 (no) 2002-10-24
CN1440410A (zh) 2003-09-03
KR20020093955A (ko) 2002-12-16
KR20090071654A (ko) 2009-07-01
TWI323733B (en) 2010-04-21
CZ301324B6 (cs) 2010-01-13
MXPA02010594A (es) 2003-05-14
EP1284976A2 (en) 2003-02-26

Similar Documents

Publication Publication Date Title
TW200617013A (en) Diazabicyclic central nervous system active agents
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
IL153297A0 (en) Compounds and compositions for delivering active agents
BR0114829A (pt) Novos compostos
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
MA27933A1 (fr) Inhibiteurs de l'activite de akt
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
TR200000197T2 (tr) Yeni bileşimler
NO20000311D0 (no) Nye forbindelser
AU2002220715A1 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
AU1816901A (en) Benzimidazole compounds having nociceptin receptor affinity
GB0111186D0 (en) Novel compounds
AU3304400A (en) Tetrahydropyran derivatives and their use as therapeutic agents
AU2001234273A1 (en) Thiazolopyrimidines and their use as modulators of chemokine receptor activity
CA2408541A1 (en) Treating eczema and/or psoriasis
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
MXPA02012263A (es) 5-aminoalquil-pirazol[4,3-d]pirimidinas.
IL137489A0 (en) Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
PT1212119E (pt) Utilizacao de ciamemazina no tratamento do desmame subito de benzodiazepinas
SI1003554T1 (en) Proton pump inhibitor in therapeutic combination with antibacterial substances
MXPA02012260A (es) 2-aminoalquil-tieno[2,3-d]pirimidinas.
DE59712297D1 (de) 3-alkylimidazopyridine